Why the study?
Ferric carboxymaltose improves biventricular systolic function in heart failure with reduced ejection fraction and iron deficiency, but its benefit on the left atrium was unknown.
Does ferric carboxymaltose improve left atrial longitudinal strain in ambulatory patients with heart failure, LVEF < 50%, and iron deficiency?
Population
53 ambulatory patients with HF, LVEF < 50%, and ID
Comparison
FCM vs placebo
Design
Post hoc subanalysis of a double-blind, placebo-controlled randomized clinical trial
Follow-up
30 days
Key result
Treatment with ferric carboxymaltose significantly improved left atrial longitudinal strain at 30 days compared with placebo in patients with heart failure and iron deficiency (MD -3.55%, P<0.001).
Authors
Loading...
Ferric carboxymaltose improves left atrial strain in iron-deficient HF; extends randomized IV iron evidence to echocardiographic LA mechanics.
RCT (n=53)
Double-blind
randomized
Does ferric carboxymaltose improve left atrial longitudinal strain in ambulatory patients with heart failure, LVEF < 50%, and iron deficiency?
Mean Difference: -3.55
Absolute Event Rate: -12% vs -8.5%
p-value: p=< 0.001
In patients with stable heart failure, LVEF < 50%, and iron deficiency, ferric carboxymaltose administration is associated with short-term improvements in left atrial longitudinal strain.
Santas et al. (2023) conducted an RCT in Heart failure with reduced ejection fraction and iron deficiency (n=53). Ferric carboxymaltose vs. Placebo was evaluated on Left atrial longitudinal strain (LA-LS) at 30 days (MD -3.55%, p=< 0.001). Treatment with ferric carboxymaltose significantly improved left atrial longitudinal strain at 30 days compared with placebo in patients with heart failure and iron deficiency (MD -3.55%, P<0.001).